Litchlab, a pioneering contract development and manufacturing organization (CDMO), today officially announced the launch of its Block Copolymer Nanoparticle Drug Delivery Platform, marking a strategic expansion into next-generation intelligent delivery systems. With the global biopharma industry seeking increasingly precise and tunable delivery technologies, Litchlab’s platform offers a flexible, scalable, and regulatory-ready solution tailored for a wide spectrum of therapeutic modalities.
The global drug delivery sector is rapidly evolving toward programmable, responsive, and long-acting nanosystems, and block copolymers—especially amphiphilic and stimulus-responsive variants—are gaining strong traction in clinical pipelines. Litchlab’s platform is aligned with this trajectory, offering custom block copolymer-based carriers capable of forming micelles, polymersomes, or hybrid nanoparticles with optimized pharmacokinetics and targeted biodistribution.
“Block copolymers offer an ideal modular architecture for achieving precise control over drug loading, release kinetics, and targeting efficiency,” said Dr. Liu Tao, Director of CDMO Operations at Litchlab. “Our platform is designed to translate this molecular precision into clinical-grade drug products with speed and compliance.”
Key Polymer Systems Supported:
PEG-b-PLA, PEG-b-PLGA, PEG-b-PCL, and other FDA-friendly amphiphilic structures
pH-/Redox-/Thermo-sensitive responsive copolymers for disease-triggered release
Charged blocks for nucleic acid encapsulation (siRNA/mRNA/ASOs)
Formulation Expertise:
Polymeric micelles (10–100 nm) for poorly soluble APIs
Polymersomes (50–200 nm) for protein, peptide, and vaccine delivery
Hybrid polymer-lipid nanoparticles for synergistic payload control
Co-delivery systems (small molecule + siRNA, protein + adjuvant)
GMP-Ready Services:
Full formulation screening & optimization
Scalable nanoprecipitation and microfluidic methods
Aseptic filling and lyophilization for long-term stability
IND/IMPD-ready CMC documentation and analytical development
| Therapeutic Area | Representative Use Case |
|---|---|
| Oncology | Tumor-targeted micellar chemotherapy |
| CNS Disorders | BBB-penetrant polymeric carriers for neurotherapeutics |
| RNA Therapeutics | Polymeric carriers for mRNA/siRNA delivery |
| Vaccines | Polymersome-based antigen delivery with controlled release |
| Autoimmune Diseases | Localized polymeric release of anti-inflammatory agents |
✅ End-to-end block copolymer nanoparticle CDMO services
✅ Proprietary libraries of smart copolymers
✅ Seamless integration with lipid and protein drug platforms
✅ Flexible scale from R&D to GMP
✅ Regulatory support across FDA, EMA, and NMPA markets
About Litchlab
Litchlab is a full-service CDMO focused on advanced drug delivery technologies including liposomes, polymer systems, hydrogel carriers, and nanoparticle engineering. By integrating high-performance materials science with global GMP standards, Litchlab empowers biopharma innovators to accelerate their complex drug programs from idea to clinic.
📩 To collaborate with Litchlab or request a capabilities brochure, contact us at sales@litchlab.com or visit www.litchlab.com.
